AKRX earnings call for the period ending September 30, 2019.
News & Analysis: Akorn
The embattled generic-pharmaceutical manufacturer earned two new product approvals.
It looks as if the company's former suitor will get a chance to run from the altar.
A judge gave Fresenius the green light to walk away from the now-infamous merger.
It's official: A judge ruled that Fresenius can abandon the previously announced acquisition of Akorn.
The rift with Fresenius continues to make headlines.
Investors received new details explaining why Fresenius dropped its acquisition. They aren't good.
The drama continues.
An issue with "data integrity" could derail a planned acquisition of the generic drugmaker.
Management confirmed that it was in buyout talks with Fresenius Kabi for the potential sale of Akorn.
An FDA reinspection of one of the company's facilities went off without a hitch.